A Phase III Study of Risk Directed Therapy for Infants with Acute Lymnphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +-FLT3 Inhibition

Conditions

Leukemia, other

What is the purpose of this trial?

This phase III ;trial ;is studying giving lestaurtinib together with combination chemotherapy to see how well it works compared to combination chemotherapy alone in treating ;infants with ;newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells or by stopping them from dividing. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) together with lestaurtinib may kill more cancer cells.


Participation Guidelines

Age:
1 Weeks - 1 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Children's Oncology Group (The)
Dates:
06/11/2013
Last Updated:
Study HIC#:
1305012077